Lung cancer is one of the malignant tumors with the highest morbidity and mortality worldwide， in which brain metastases are a common complication of advanced lung cancer， significantly affecting the quality of life and survival of patients. With the development of genomics technologies such as genomics， transcriptomics， proteomics and metabolomics， research on lung cancer brain metastases has gradually deepened. The trans-omics approach systematically resolves tumor molecular features by integrating genome sequencing， single-cell transcriptome analysis， high-throughput mass spectrometry proteomics， and metabolite profiling analysis， and reveals the molecular mechanisms of brain metastases of lung cancer in a multidimensional way， which provides a significant advantage in early diagnosis. Radiomics combined with multi-omics data allows early identification of patients with asymptomatic brain metastases and dynamic monitoring of treatment response by metabolic markers（ e.g. GSH， AKR1B10）. Genomic analysis of circulating tumor DNA in blood or cerebrospinal fluid can detect genetic mutations associated with lung cancer brain metastases for early warning. Transcriptome combined with proteomics analysis can identify specific gene expression profile changes and provide molecular markers for early diagnosis. Based on trans-omics diagnosis， this paper reviews the data from multi-omics studies by integrating them and explore their potential application and clinical translation in precision medicine， with a view to providing new ideas and references for trans-omics diagnosis of brain metastases in lung cancer.